• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

IOVANCE BIOTHERAPEUTICS, INC.

Notes

No. Proposition For Against Abstain
1

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Iain Dukes, D. Phil.

2

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

3

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Ryan Maynard

4

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Wayne P. Rothbaum

5

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

6

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

7

Election of Director to serve until the 2026 Annual Meeting of Stockholders: Wendy Yarno

8

To approve, by non-binding advisory vote, the compensation of our named executive officers.

9

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.

10

To approve an amendment to our 2018 Equity Incentive Plan to increase the number of shares of the Companys common stock authorized for issuance thereunder by 12,500,000 shares.

11

To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Companys common stock authorized for issuance thereunder by 1,000,000 shares.